scholarly journals Quantitative assessment of crystal dissolution in gout during urate-lowering therapy with computer-aided MicroPure imaging: a cohort study

2021 ◽  
Vol 9 (18) ◽  
pp. 1444-1444
Author(s):  
Qiao Wang ◽  
Hui Bao ◽  
Le-Hang Guo ◽  
Feng-Shan Jin ◽  
Xiao-Long Li ◽  
...  
Andrologia ◽  
2018 ◽  
Vol 50 (10) ◽  
pp. e13141 ◽  
Author(s):  
Farren Hardneck ◽  
Gadieja Israel ◽  
Edmund Pool ◽  
Liana Maree

2020 ◽  
Vol 2020 ◽  
pp. 1-13
Author(s):  
Yi-Jen Fang ◽  
Tien-Yuan Wu ◽  
Cheng-Li Lin ◽  
Chih-Yang Su ◽  
Jia-Rong Li ◽  
...  

Patients with gout are at a higher risk of cardiovascular disease, which is associated with hyperlipidemia. Management of gout in Taiwan is poor, and the association between urate-lowering therapy (ULT) among gout patients and hyperlipidemia is unclear. We conducted a retrospective cohort study using data from the Longitudinal Health Insurance Database (LHID) of Taiwan on new-onset gout patients and a comparison cohort without gout. A Cox proportional hazards model was used to analyze differences in the risk of hyperlipidemia between patients with and without gout after considering related comorbidities. We also examined the ULT medications on the hepatic expression of lipogenesis-related genes. After adjusting for potential confounders, the case group (44,413 patients) was found to have a higher risk of hyperlipidemia than the control cohort (177,652 patients) [adjusted hazards ratio aHR = 2.55 ]. Gout patients without antigout treatment had significantly higher risk of hyperlipidemia than the control cohort ( aHR = 3.10 ). Among gout patients receiving ULT, except those receiving probenecid ( aHR = 0.80 ), all had significantly lower risk of hyperlipidemia than gout patients without ULT (all aHR < 0.90 ). Using real-time polymerase chain reaction, we found that most of the antigout drugs decreased the expression of hepatic genes related to lipogenesis in differentiated HepaRG cells. These data indicate that these antigout drugs reduce hyperlipidemia in gout patients, partly via the reduction in expression of lipogenesis-related genes, leading to improved blood lipid profiles. We provide evidence of the strong association between gout and hyperlipidemia and highlight the need for appropriate treatment guidelines.


PLoS ONE ◽  
2012 ◽  
Vol 7 (2) ◽  
pp. e31602 ◽  
Author(s):  
Fangfang Liu ◽  
Fangcen Guo ◽  
Yue Zhou ◽  
Zhonghu He ◽  
Xiuyun Tian ◽  
...  

2021 ◽  
Vol 8 ◽  
Author(s):  
Longxiang Cao ◽  
Jing Zhou ◽  
Mingzhi Chen ◽  
Tao Chen ◽  
Man Liu ◽  
...  

Background: Acute pancreatitis (AP) is a potentially life-threatening inflammatory disease with multiple etiologies. The prevalence of hypertriglyceridemia-induced acute pancreatitis (HTG-AP) has been increasing in recent years. It is reported that early triglyceride (TG) levels were associated with the severity of the disease, and TG- lowering therapies, including medical treatment and blood purification, may impact the clinical outcomes. However, there is no consensus regarding the optimal TG-lowering therapy, and clinical practice varies greatly among different centers. Our objective is to evaluate the TG-lowering effects of different therapies and their impact on clinical outcomes in HTG-AP patients with worrisome features.Methods: This is a multicenter, observational, prospective cohort study. A total of approximately 300 patients with HTG-AP with worrisome features are planned to be enrolled. The primary objective of the study is to evaluate the relationship between TG decline and the evolution of organ failure, and patients will be dichotomized depending on the rate of TG decline. The primary outcome is organ failure (OF) free days to 14 days after enrollment. Secondary outcomes include new-onset organ failure, new-onset multiple-organ failure (MOF), new-onset persistent organ failure (POF), new receipt of organ support, requirement of ICU admission, ICU free days to day 14, hospital free days to day 14, 60-day mortality, AP severity grade (Based on the Revised Atlanta Classification), and incidence of systemic and local complications. Generalized linear model (GLM), Fine and Gray competing risk regression, and propensity score matching will be used for statistical analysis.Discussion: Results of this study will reveal the current practice of TG-lowering therapy in HTG-AP and provide necessary data for future trials.


2018 ◽  
Vol 106 (3) ◽  
pp. 286-295 ◽  
Author(s):  
J. Thereaux ◽  
T. Lesuffleur ◽  
S. Czernichow ◽  
A. Basdevant ◽  
S. Msika ◽  
...  

PLoS ONE ◽  
2015 ◽  
Vol 10 (12) ◽  
pp. e0145193 ◽  
Author(s):  
Jiunn-Horng Chen ◽  
Joung-Liang Lan ◽  
Chi-Fung Cheng ◽  
Wen-Miin Liang ◽  
Hsiao-Yi Lin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document